Výsledky vyhledávání - "Frankie Holmes"

Supplementary Data from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Protocol 12 Supplement File

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::068c2c44bf3d18993f6102c57b3248ef
https://doi.org/10.1158/1078-0432.22476942.v1

Zobrazit plný text záznamu

Data from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Purpose:To determine whether the androgen receptor (AR) inhibitor, enzalutamide, improves effectiveness of endocrine therapy (ET) in hormone receptor–positive (HR+) breast cancer.Patients and Methods:In this phase II trial, patients with HR+/HER2 n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d318f28e0ad3839d4428063e380ec30
https://doi.org/10.1158/1078-0432.c.6529533

Zobrazit plný text záznamu

Supplementary Figure 3 from A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer

Plasma trough concentrations by week for (A) enzalutamide and (B) exemestane The labeled values denote mean (SD). The open circles denote trough concentration values of individual patients. Solid squares and vertical lines denote mean with error bars

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3118ee709fe5edc4ba5c93566d4e81cf
https://doi.org/10.1158/1078-0432.22476930.v1

Zobrazit plný text záznamu

Supplementary Materials from A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Contains supplementary tables and methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::355b3c9ba3ae1a5cd1e94863c31b57cd
https://doi.org/10.1158/1078-0432.22468854.v1

Zobrazit plný text záznamu

Data from A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB)

Purpose:Addition of alpelisib to fulvestrant significantly extended progression-free survival in PIK3CA-mutant, hormone receptor–positive (HR+) advanced/metastatic breast cancer in the phase III SOLAR-1 study. The combination of alpelisib and letro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::511e783ef87ce76ed5b7a1705fbc29cf
https://doi.org/10.1158/1078-0432.c.6527076.v1

Zobrazit plný text záznamu

Use of Safety-Modified Retroviruses to Introduce Chemotherapy Resistance Sequences into Normal Hematopoietic Cells for Chemoprotection During the Therapy of Breast Cancer: A Pilot Trial. M.D. Anderson Cancer Center, Houston, Texas

Autor: Albert B. Deisseroth, Frankie Holmes, Gabriel Hortobagyi, Richard Champlin

Publikováno v: Human Gene Therapy. 7:401-416

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1594de9816b208c7bf7b886427f0b964
https://doi.org/10.1089/hum.1996.7.3-401

Zobrazit plný text záznamu

High-Dose Chemotherapy Intensification with Bone Marrow Support for Hormone Receptor Negative or Hormonal Refractory Relapsing Breast Cancer

Autor: Frank R. Dunphy, Gary Spitzer, Aman U. Buzdar, Gabriel N. Hortobagyi, Frankie Holmes, Leonard J. Horwitz, Jonathan C. Yau, Jorge A. Spinolo, Sundar Jagannath, Karel A. Dicke

Publikováno v: Breast Cancer: Progress in Biology, Clinical Management and Prevention ISBN: 9781461288947

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::af9ee77528a08e25b0d268f6c9dc44a6
https://doi.org/10.1007/978-1-4613-1617-6_11

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání